MedWatch forms continued
This article was originally published in The Tan Sheet
Executive SummaryFDA asks the Office of Management and Budget for a three-year extension of the MedWatch form for mandatory reports from firms marketing medical devices, Rx and OTC drugs and dietary supplements. In a Sept. 24 Federal Register notice, the agency says the instructions on the MedWatch form will be changed to reflect that AERs for OTCs and supplements now are mandatory (1"The Tan Sheet" Dec. 18, 2006, p. 4). No changes are proposed for "any content or formatting," the notice says. Dietary supplement industry stakeholders told FDA that the MedWatch form was developed for reporting pharmaceutical adverse events, but including all information relevant to some supplement-related events customers report will be difficult with the current form. The deadline for comments on the notice is Oct. 24
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.